Effect of rosuvastatin on outcomes in chronic haemodialysis patients - Design and rationale of the AURORA study

Bengt Fellström, Faiez Zannad, Roland Schmieder, Hallvard Holdaas, Alan Jardine, Helen Rose, Wim Wilpshaar, K. Bannister, J. Beutler, D. Chae, S. M. Cobbe, B. Espinoza Vazquez, C. Gronhagen-Riska, J. Lima, R. Lins, A. McMahon, G. Mayer, H. Parving, G. Remuzzi, O. SamuelssonS. Sonkodi, G. Suleymanlar, V. Tesar, D. Tsakiris, V. Todorov, A. Wiecek, R. Wûthrich, H. Dargie, E. Ritz, H. Wedel, A. H. Zwinderman, A. Brady, C. Deighan, A. Gaw, P. Macfarlane, D. Stott

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Background: Patients with end-stage renal disease (ESRD) are at high risk of cardiovascular events. Multiple risk factors for atherosclerosis are present in ESRD and may contribute to the increased risk of cardiovascular mortality in this population. In contrast to patients with normal trend function the benefits of modifying lipid levels on cardiovascular outcomes in patients with ESRD on haemodialysis have yet to be confirmed in large prospective randomised trials. A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events (AURORA) will be the first large-scale international trial to assess the effects of statin therapy on cardiovascular morbidity and mortality in ESRD patients on chronic haemodialysis. Methods: More than 2,750 ESRD patients who have been receiving chronic haemodialysis treatment for at least 3 months have been randomised (1:1), irrespective of baseline lipid levels, to treatment with rosuvastatin 10 mg or placebo. The primary study endpoint is the time to a major cardiovascular event (first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke). Secondary endpoints include all-cause mortality, major cardiovascular event-free survival time, time to cardiovascular death, time to non-cardiovascular death, cardiovascular interventions, tolerability of treatment and health economic costs per life-year saved. Study medication will be given until 620 subjects have experienced a major cardiovascular event. Conclusion: Our hypothesis is that results from AURORA will establish the clinical efficacy and tolerability of rosuvastatin in patients with ESRD receiving chronic haemodialysis and guide the optimal management of this expanding population.

Original languageEnglish
Article number9
JournalCurrent Controlled Trials in Cardiovascular Medicine
Volume6
DOIs
Publication statusPublished - May 23 2005

    Fingerprint

Keywords

  • Atherosclerosis
  • Cardiovascular disease
  • End-stage renal disease
  • Haemodialysis
  • Lipids
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Fellström, B., Zannad, F., Schmieder, R., Holdaas, H., Jardine, A., Rose, H., Wilpshaar, W., Bannister, K., Beutler, J., Chae, D., Cobbe, S. M., Vazquez, B. E., Gronhagen-Riska, C., Lima, J., Lins, R., McMahon, A., Mayer, G., Parving, H., Remuzzi, G., ... Stott, D. (2005). Effect of rosuvastatin on outcomes in chronic haemodialysis patients - Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine, 6, [9]. https://doi.org/10.1186/1468-6708-6-9